Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Pharmaceutical Equivalents

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.

Drug Nomenclature

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluating Pesticide Applicator Training in Spanish: An Oregon Interagency Pilot.

Journal of agromedicine·2025

Same author

Florida hospitals' volume response to Medicare's Outpatient Prospective Payment System.

Findings brief : health care financing & organization·2013

Same author

Reducing prenatal smoking: the role of state policies.

Findings brief : health care financing & organization·2012

Same author

Pay-for-performance programs to reduce racial/ethnic disparities: limitations of a one-size-fits-all approach.

Findings brief : health care financing & organization·2012

Same author

The effect of health information technology on quality in U.S. hospitals.

Findings brief : health care financing & organization·2012

Same author

Undocumented immigrants, left out of health reform, likely to continue to grow as a share of the uninsured.

Findings brief : health care financing & organization·2011

Search research articles

Related Experiment Video

Updated: May 16, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Encouraging generic use can yield significant savings.

Christina Zimmerman¹

¹Changes in Health Care Financing & Organization (HCFO), USA. christina.zimmerman@academyhealth.org

Findings Brief : Health Care Financing & Organization

|December 11, 2012

Summary

Zero copayment for generic drugs significantly boosts generic statin use. Policies like prior authorization for brand-name statins also encourage generic statin utilization, ultimately lowering healthcare costs for all stakeholders.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Experiment Videos

Last Updated: May 16, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Area of Science:

Health Economics
Pharmaceutical Policy
Clinical Pharmacy

Background:

Generic statin utilization is crucial for cost containment in cardiovascular pharmacotherapy.
Understanding factors influencing generic statin uptake is essential for optimizing drug formularies and patient access.

Purpose of the Study:

To identify key financial and regulatory factors impacting the utilization of generic statins.
To inform policy decisions aimed at increasing generic statin use and reducing healthcare expenditures.

Main Methods:

Analysis of prescription data to correlate copayment levels and utilization management strategies with generic statin prescribing patterns.
Statistical modeling to assess the influence of different policy interventions on generic drug adoption.

Main Results:

Zero copayment for generic drugs emerged as the strongest predictor of increased generic statin utilization.
Higher generic drug copayments and lower brand-name drug copayments were linked to reduced generic statin use.
Prior authorization and step therapy requirements for branded statins were associated with a higher probability of generic statin use.

Conclusions:

Financial incentives, particularly copayment elimination, are powerful drivers of generic statin adoption.
Regulatory levers, such as prior authorization, can effectively promote the use of cost-saving generic alternatives.
Increased generic statin utilization offers significant cost-reduction opportunities for patients, insurance plans, and Medicare.